Cancer and the potential place for growth hormone receptor antagonist therapy.
Pegvisomant is a recombinant protein, structurally similar to natural human growth hormone (GH), which is capable of binding to the GH receptor as a competitive antagonist. As well as being evaluated for the treatment of acromegaly, pegvisomant is being investigated as a possible antineoplastic agent, initially in mice. So far, in vitro efficacy against meningioma and in vivo efficacy against colon and breast cancer cell lines have been examined.
Friend
K E
KE
MD Anderson Cancer Center, University of Texas, Houston, USA. Keith.Friend@am.pnu.com
D000818:Animals; D001943:Breast Neoplasms / Q000378:metabolism; D019382:Human Growth Hormone / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008579:Meningioma / Q000188:drug therapy; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy*; D011986:Receptors, Somatotropin / Q000037:antagonists & inhibitors*; D014407:Tumor Cells, Cultured
D011986:Receptors, Somatotropin; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I; C406545:pegvisomant